Table 2.
Association between body mass index at diagnosis and endometrial tumor dichotomous ER status (n=346)
| ER Cut Point | BMI Coding (kg/m2)a | ||||
|---|---|---|---|---|---|
| # (%) | >=25 vs. <25 | >=30 vs. <30 | |||
| ER+ | OR | 95% CI | OR | 95% CI | |
| 0% | 303 (88%) | 1.29 | 0.60, 2.75 | 2.83 | 1.26, 6.37 |
| 5% | 299 (86%) | 1.45 | 0.70, 2.99 | 2.84 | 1.31, 6.17 |
| 10% | 298 (86%) | 1.36 | 0.66, 2.80 | 2.92 | 1.34, 6.33 |
| 15% | 294 (85%) | 1.23 | 0.61, 2.48 | 2.69 | 1.30, 5.58 |
| 20% | 286 (83%) | 0.92 | 0.47, 1.82 | 2.40 | 1.22, 4.74 |
| 25% | 276 (80%) | 0.96 | 0.51, 1.80 | 1.78 | 0.96, 3.31 |
| 30% | 267 (77%) | 0.93 | 0.51, 1.70 | 1.54 | 0.86, 2.75 |
| 35% | 264 (76%) | 0.85 | 0.46, 1.56 | 1.44 | 0.81, 2.58 |
| 40% | 258 (75%) | 0.91 | 0.51, 1.63 | 1.35 | 0.78, 2.36 |
| 45% | 250 (72%) | 0.79 | 0.44, 1.41 | 1.17 | 0.68, 1.99 |
| 50% | 245 (71%) | 0.79 | 0.45, 1.40 | 1.10 | 0.65, 1.87 |
| 55% | 237 (68%) | 0.98 | 0.57, 1.69 | 1.22 | 0.73, 2.04 |
| 60% | 228 (66%) | 0.93 | 0.54, 1.60 | 1.15 | 0.69, 1.90 |
| 65% | 218 (63%) | 0.96 | 0.57, 1.62 | 1.08 | 0.66, 1.76 |
| 70% | 201 (58%) | 1.00 | 0.60, 1.68 | 1.06 | 0.65, 1.72 |
| 75% | 176 (51%) | 0.98 | 0.58, 1.63 | 0.94 | 0.58, 1.52 |
| 80% | 149 (43%) | 1.14 | 0.68, 1.93 | 1.00 | 0.61, 1.63 |
| 85% | 124 (36%) | 1.23 | 0.72, 2.11 | 1.08 | 0.65, 1.79 |
| 90% | 103 (30%) | 1.36 | 0.76, 2.42 | 1.31 | 0.77, 2.23 |
| 95% | 59 (17%) | 1.51 | 0.74, 3.10 | 1.63 | 0.87, 3.04 |
# (%) ER+ = number (percentage) of patients (out of 346) with ER expression at or above the cut point, except for a cut point of 0% where ER+ is only those above the cut point. ER expression measured as semi-continuous percent positive cells (0–100%), then dichotomized to ER+ and ER− groups.
Each estimate is the BMI result from a separate model with a dependent variable of dichotomous tumor ER status (ER+ vs. ER−) defined by the respective cut point, and with independent variables of BMI (either [>=30 vs. <30] or [>=25 vs. <25] but not both), years of E-Only HT Use (continuous), years of E+P HT Use (continuous), years of Other HT Use (continuous), years of oral contraceptive use (continuous), current smoker (yes/no), former smoker (yes/no), pack-years of cigarettes smoked (continuous), diabetes (yes/no), family history of endometrial cancer (yes/no), parity (continuous), years from menarche to menopause (continuous), years since menopause (continuous). HT results from the same sets of models are presented in Supplemental Tables S2 and S4.
ER=Estrogen Receptor, E-Only=Unopposed Estrogen, E+P=Estrogen plus Progesterone, HT=Hormone Therapy, BMI=Body Mass Index